BRAF and melanoma: For patients with BRAF-mutant melanoma receiving MAPK inhibition-targeted therapy, drug resistance would inevitably occur within 6–12 months, which significantly hinders the treatment efficacy and result in frequent recurrence.406 Based on the distinct mechanisms and characteristics, resistance to MAPK inhibition therapy is classified to three types including intrinsic resistance, adaptive resistance and acquired resistance.